

W T S

ARTICLE DELIVERY

WTS Number: 143196



Order #126159

Request Date: 10/27/2016 04:49pm
Requester: Heather O'Dea - Paul Hastings LLP
Phone: 2123186817
Reference: S. Peachman #92125.00004
Delivery email: heatherodea@paulhastings.com
Instructions:

4-hour rush

Estimated Delivery:
10/28/2016 10:00am

Maxcost: 80.00

Citation:

R. Lfberg, Oral formulation of budesonide for IBD, 15 RES. CLIN. FORUM, 91-96 (1996).

Library/Supplier: IN PAT-10023050

ISSN/ISBN/OCLC: 0143-3083; CRD

Base Service Fee: \$15 **Rush fee:** \$20.00

Copyright: WTS will pay copyright royalties and bill me: \$ _____ pages: _____

Supplier: WTS staff may obtain materials from outside UW - Madison: \$ _____

Shipping: \$ _____ **Research:** \$ _____

THIS IS NOT AN INVOICE

Research and Clinical Forums

VOLUME 15 NUMBER 5 1993
ISSN 0143-3083

U of MN
Bio-Medical
Library

3/4 /96


REVIEWING STEROIDS IN THE
TREATMENT OF IBD



WELLS MEDICAL

DOCKET
A L A R M

Find authenticated court documents without watermarks at docketalarm.com.



General Information

Research and Clinical Forums is an international journal devoted to publishing, in the English language, material presented and discussed at medico-scientific and medico-therapeutic congresses and symposia, either in the form of selected and collated papers, or as full reports and proceedings. Each issue is devoted to one subject area and may consist of the proceedings of, or selected papers from, one particular meeting or may be a compilation of material which, while relating to a particular subject, may have been presented at a number of meetings.

Material presented at congresses, symposia or meetings held anywhere in the world is considered for publication, the basic criterion for acceptance being the scientific and medical standard of the material. Each issue of *Research and Clinical Forums* is edited by an independent authority, or panel of assessors, expert in the relevant field. Views and factual claims expressed in individual contributions are personal to the respective contributor and are not necessarily endorsed by the Editors, Advisers, Assessors, Publishers, Distributors or Sponsors.

Research and Clinical Forums is published periodically to demand, is distributed to medical schools, medical libraries, hospitals and research establishments world-wide, and to all information and retrieval systems.

Where necessary, issues of *Research and Clinical Forums* will be translated into languages other than English and published as foreign language editions of those issues.

Copyright © 1993 by
Wells Medical Ltd
Chapel Place
Royal Tunbridge Wells
Kent TN1 1BP
England

All rights reserved. This publication is copyright under the Berne Convention and the International Copyright Convention. Apart from any fair dealing under the UK Copyright Act 1956, Part 1, Section 7, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means without the prior permission of the Publisher.

Although great care has been taken in compiling and checking the information given in this publication to ensure that it is accurate, the Publisher shall not be held responsible for the continued currency of the information or for any errors, omissions or inaccuracies in this publication. Due to the rapid advances in medical science, it is recommended that independent verification of diagnoses and drug dosages should be made. In addition, no responsibility is assumed by the Publisher for any injury and/or damage to persons or property arising from any methods, products, instructions, ideas or otherwise contained in this publication.

Notes for Contributors see inside back cover.

The Publishing Editor
Research and Clinical Forums
Chapel Place
Royal Tunbridge Wells
Kent TN1 1BP

British Library Cataloguing in Publications Data
Research and Clinical Forums
Volume 15, No. 5

1. Medicine-Periodicals 2. Inflammatory bowel disease
3. Ulcerative colitis 4. Crohn's disease 5. Corticosteroids
610'.5 R3J
ISBN 1 869969 82 0
ISSN 0143-3083

Research and Clinical Forums is indexed in *Current Contents/Clinical Practice*, the *Index of Scientific and Technical Proceedings*, *Index Medicus* and abstracted in *Chemical Abstracts*.

This material may be protected by Copyright law (Title 17 U.S. Code)

Oral formulation of budesonide for IBD

R. Löfberg, PhD, MD

Unit of Gastroenterology
Huddinge University Hospital
Karolinska Institute
Stockholm
Sweden

SUMMARY

The oral formulation of budesonide for the treatment of inflammatory bowel disease was developed as a continuation of the development of budesonide enema for the treatment of distal ulcerative colitis. An oral formulation of budesonide has been designed with an acid-resistant coating to prevent release in the stomach. This formulation, budesonide CIR (controlled ileal release) capsule, was designed for the treatment of ileocaecal Crohn's disease. Pharmacokinetic studies have shown that the majority of budesonide CIR is absorbed in the terminal ileum and caecum, regardless of the food regimen. The tissue affinity of budesonide for the bowel mucosa has not yet been studied. Clinical trials presently suggest that budesonide CIR is as efficacious as oral prednisolone and causes fewer side effects and less adrenal gland suppression. It remains to be established whether this oral formulation of budesonide will be advantageous in the long-term treatment of active ileocaecal Crohn's disease.

INTRODUCTION

The anti-inflammatory effect of glucocorticosteroids (GCS) in inflammatory bowel disease (IBD), particularly in moderate and severe disease, is unsurpassed by any other type of drug. The clinical response is substantial and usually rapid (within days). Unfortunately, long-term treatment with prednisolone doses of greater than 7.5–10 mg/daily is precluded by the risk of hazardous complications such as osteoporosis, diabetes mellitus and hypertension. Systemic side effects are not uncommon, and may be troublesome, even during short-term treatment. If these systemic problems could be overcome or markedly reduced, GCS may become a more attractive option both for short- and long-term treatment of IBD.

The topically-acting steroid, budesonide, given as an enema, has been proven to be beneficial in mild to moderately active distal ulcerative colitis (UC) and proctitis and causes no, or only limited, depression of endogenous plasma cortisol levels^{1,2}. Furthermore, corticosteroid-related side effects associated with treatment with budesonide enema have been rare and mild^{1,2}. The enema preparation however, is not suitable for patients with extensive IBD, ie. total UC or Crohn's disease (CD) in the small bowel and/or proximal colon, because the active drug will not spread proximally beyond the splenic flexure. Budesonide, given as a plain tablet, is rapidly and completely absorbed in the proximal small bowel and is extensively metabolised in the liver, via the cytochrome-P₄₅₀ 3A system.

involving the small bowel and proximal and transverse colon, provided that it is delivered to the affected bowel segment(s) and at a sufficient dose. Since the intestinal blood flow is predominantly drained *via* the portal vein, the amount of budesonide reaching the systemic circulation would be low due to the high first-pass metabolism in the liver.

DEVELOPMENT OF AN ORAL FORMULATION OF BUDESONIDE

Budesonide was initially developed for use in the airways, but in 1986, an oral formulation for the treatment of extensive IBD was produced. The development of such a formulation took place in parallel with the work on the budesonide enema for the treatment of distal UC. The primary target for the oral formulation was CD, localised to the terminal ileum and proximal colon. The only efficacious treatment for this disease hitherto available, had been either surgery (ie. resection of the diseased bowel segment) or treatment with moderate to high doses of conventional GCS. The topically-acting steroid, budesonide, appeared to offer potential for a better efficacy *versus* side effect ratio.

A primary aim of the oral formulation of budesonide was to deliver most of the active drug to the site of inflammation. The oral formulation of budesonide is therefore acid-resistant to prevent release in the stomach and release should not begin until the formulation had passed into the small bowel. For ileocaecal CD, the active drug ideally should be released in the terminal ileum and the proximal third of the colon.

The gastric emptying of different dosage formulations is variable and dependent upon the type of formulation itself and the type of meal taken at the time of dosing. Heavy meals, high in fat content, increase the time of gastric emptying. Tablets may remain in the stomach for a substantial period of time, ie. several hours, whereas small pellets empty in a more rapid and regular fashion and are not greatly affected by the digestive state of the individual⁴. Pellets also spread into the small intestine. To prevent the release of the active drug in the stomach, pellets are covered with an acid-resistant layer called an enteric coating.

In contrast to gastric emptying, small bowel transit time appears to be constant and independent of the dosage or the calorific content of the concomitant meal⁴. The average small bowel transit time is between 3–4 hours (range: 2–5 hours) for solutions, pellets or single units⁵. The transit time through the small bowel appears to be unchanged following ileocolonic resection⁶. In patients with active CD of the small bowel or with terminal ileal resection, no differences in gastric emptying or small bowel transit time compared with normal controls were detected in a scintigraphic study using ¹¹¹Indium⁷. It appears that the small bowel transit time of patients with CD confined to the ileocolonic region, with or without previous ileocaecal resection, averages 3.5 hours.

An oral formulation of budesonide destined for use in the treatment of ileocaecal CD was designed to release the main proportion of budesonide approximately three hours after stomach emptying. This formulation consisted of sustained-release pellets with an enteric coating which were called budesonide CIR (controlled ileal release).

COMPOSITION OF BUDESONIDE CIR PELLETS

The CIR pellets are about 1 mm in size and consist of a sugar core over which budesonide and an insoluble polymer is sprayed in a fluid bed dryer. The insoluble polymer serves as rate-control for the release of budesonide. A 10–20 micron thick enteric coating (Eudragit

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.